Policy1-Cervix is an extensively validated dynamic model of HPV transmission, HPV vaccination, cervical precancer, cancer survival, screening, diagnosis and treatment. The Policy1-Cervix model has directly informed more than 10 specific national-level policy decisions in Australia, England and NZ, and related planning and budgeting processes. It is currently being used to inform long-term planning and target setting by the WHO. The model has been used for a number of HPV vaccine evaluations, including effectiveness and cost-effectiveness of HPV vaccination in both girls and boys, taking into account catch-up vaccination, as well as the effectiveness and cost-effectiveness of the next generation nonavalent vaccine. The model has also been used to perform screening technology, screening interval and screening management evaluations performed on behalf of national cervical screening programs in Australia, New Zealand and England. These evaluations include assessing the impact of test-of-cure management in women after treatment for CIN2/3, evaluating primary HPV testing versus cytology, evaluating triage management options for HPV positive women, and estimating the transitional fluctuations in health outcomes and resource use for countries transitioning to longer-interval HPV testing. It has also been used to evaluate the effectiveness and cost-effectiveness of screening and vaccination in both rural and urban China, urban and rural Vietnam as well as the potential impact of screening and HPV vaccination on a global scale. The model is currently being expanded to account for different natural history for HIV positive women through the development of an HIV-HPV model platform.